Profile of intraocular tumour necrosis factor-α and interleukin-6 in diabetic subjects with different degrees of diabetic retinopathy

Acta Ophthalmologica

Volumn 91, Issue 5, 2013, Pages 445-452

  Gustavsson, Carin ^a   Agardh, Carl David ^a   Agardh, Elisabet ^a  

^a LUND UNIVERSITY HOSPITAL   (Sweden)

Author keywords

aqueous humour; diabetic retinopathy; inflammation; interleukin 6; tumour necrosis factor ; vitreous

Indexed keywords

ANGIOTENSIN RECEPTOR ANTAGONIST; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; INTERLEUKIN 1BETA; INTERLEUKIN 6; PROTEIN KINASE C; TUMOR NECROSIS FACTOR ALPHA;

ADULT; AGED; ALBUMINURIA; ARTICLE; CATARACT; CONTROLLED STUDY; CYTOKINE PRODUCTION; DIABETIC RETINOPATHY; DISEASE SEVERITY; ENZYME LINKED IMMUNOSORBENT ASSAY; EPIRETINAL MEMBRANE; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; PATHOGENESIS; PRIORITY JOURNAL; PROTEIN ANALYSIS; PROTEIN BLOOD LEVEL; VITRECTOMY; VITREOUS BODY; VITREOUS HEMORRHAGE; WAIST CIRCUMFERENCE;

AQUEOUS HUMOUR; DIABETIC RETINOPATHY; INFLAMMATION; INTERLEUKIN-6; TUMOUR NECROSIS FACTOR-Α; VITREOUS;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; AQUEOUS HUMOR; CHILD; CHILD, PRESCHOOL; DIABETIC RETINOPATHY; ENZYME-LINKED IMMUNOSORBENT ASSAY; FEMALE; HUMANS; INFLAMMATION MEDIATORS; INTERLEUKIN-6; MALE; MIDDLE AGED; PHOTOMETRY; SEVERITY OF ILLNESS INDEX; TUMOR NECROSIS FACTOR-ALPHA; VITREOUS BODY; YOUNG ADULT;

EID: 84880303028     PISSN: 1755375X     EISSN: 17553768     Source Type: Journal    
DOI: 10.1111/j.1755-3768.2012.02430.x     Document Type: Article

References (44)

1. Abu el Asrar AM, Maimone D, Morse PH, Gregory S, &, Reder AT, (1992): Cytokines in the vitreous of patients with proliferative diabetic retinopathy. Am J Ophthalmol 114: 731-736.
2. Adamiec-Mroczek J, &, Oficjalska-Mlynczak J, (2008): Assessment of selected adhesion molecule and proinflammatory cytokine levels in the vitreous body of patients with type 2 diabetes-role of the inflammatory-immune process in the pathogenesis of proliferative diabetic retinopathy. Graefes Arch Clin Exp Ophthalmol 246: 1665-1670.
3. Adamiec-Mroczek J, Oficjalska-Mlynczak J, &, Misiuk-Hojlo M, (2010): Roles of endothelin-1 and selected proinflammatory cytokines in the pathogenesis of proliferative diabetic retinopathy: analysis of vitreous samples. cytokine 49: 269-274.
4. Adamis AP, &, Berman AJ, (2008): Immunological mechanisms in the pathogenesis of diabetic retinopathy. Semin Immunopathol 30: 65-84.
5. Aiello LP, Avery RL, Arrigg PG, et al., (1994): Vascular endothelial growth factor in ocular fluid of patients with diabetic retinopathy and other retinal disorders. N Engl J Med 331: 1480-1487.
6. Anfossi G, Russo I, Doronzo G, Pomero A, &, Trovati M, (2010): Adipocytokines in atherothrombosis: focus on platelets and vascular smooth muscle cells. Mediators Inflamm 2010: 174341.
7. Aveleira CA, Lin CM, Abcouwer SF, Ambrosio AF, &, Antonetti DA, (2010): TNF-alpha signals through PKCzeta/NF-kappaB to alter the tight junction complex and increase retinal endothelial cell permeability. Diabetes 59: 2872-2882.
8. Ben-Mahmud BM, Chan WH, Abdulahad RM, Datti A, Orlacchio A, Kohner EM, &, Chibber R, (2006): Clinical validation of a link between TNF-alpha and the glycosylation enzyme core 2 GlcNAc-T and the relationship of this link to diabetic retinopathy. Diabetologia 49: 2185-2191.
9. Bertazza L, &, Mocellin S, (2008): Tumor necrosis factor (TNF) biology and cell death. Front Biosci 13: 2736-2743.
10. Brownlee M, (2001): Biochemistry and molecular cell biology of diabetic complications. Nature 414: 813-820.
11. Canataroglu H, Varinli I, Ozcan AA, Canataroglu A, Doran F, &, Varinli S, (2005): Interleukin (IL)-6, interleukin (IL)-8 levels and cellular composition of the vitreous humor in proliferative diabetic retinopathy, proliferative vitreoretinopathy, and traumatic proliferative vitreoretinopathy. Ocul Immunol Inflamm 13: 375-381.
12. Chibber R, Ben-Mahmud BM, Chibber S, &, Kohner EM, (2007): Leukocytes in diabetic retinopathy. Curr Diabetes Rev 3: 3-14.
13. Dengler J, Schefold JC, Graetz D, Meisel C, Splettstosser G, Volk HD, &, Schlosser HG, (2008): Point-of-care testing for interleukin-6 in cerebro spinal fluid (CSF) after subarachnoid haemorrhage. Med Sci Monit 14: BR265-BR268.
14. Dinarello CA, (2005): Interleukin-1beta. Crit Care Med 33: S460-S462.
15. Doganay S, Evereklioglu C, Er H, Turkoz Y, Sevinc A, Mehmet N, &, Savli H, (2002): Comparison of serum NO, TNF-alpha, IL-1beta, sIL-2R, IL-6 and IL-8 levels with grades of retinopathy in patients with diabetes mellitus. Eye 16: 163-170.
16. Ehrlich R, Harris A, Ciulla TA, Kheradiya N, Winston DM, &, Wirostko B, (2010): Diabetic macular oedema: physical, physiological and molecular factors contribute to this pathological process. Acta Ophthalmol 88: 279-291.
17. ETDRS group (1991): Grading diabetic retinopathy from stereoscopic color fundus photographs-an extension of the modified Airlie House classification. ETDRS report number 10. Early Treatment Diabetic Retinopathy Study Research Group. Ophthalmology 98: 786-806.
18. Franks WA, Limb GA, Stanford MR, Ogilvie J, Wolstencroft RA, Chignell AH, &, Dumonde DC, (1992): Cytokines in human intraocular inflammation. Curr Eye Res 11 (Suppl): 187-191.
19. Funatsu H, Yamashita H, Noma H, Mimura T, Yamashita T, &, Hori S, (2002): Increased levels of vascular endothelial growth factor and interleukin-6 in the aqueous humor of diabetics with macular edema. Am J Ophthalmol 133: 70-77.
20. Funatsu H, Noma H, Mimura T, Eguchi S, &, Hori S, (2009): Association of vitreous inflammatory factors with diabetic macular edema. Ophthalmology 116: 73-79.
21. Funding M, Hansen TK, Gjedsted J, &, Ehlers N, (2006): Simultaneous quantification of 17 immune mediators in aqueous humour from patients with corneal rejection. Acta Ophthalmol Scand 84: 759-765.
22. Goldberg RB, (2009): Cytokine and cytokine-like inflammation markers, endothelial dysfunction, and imbalanced coagulation in development of diabetes and its complications. J Clin Endocrinol Metab 94: 3171-3182.
23. Googe J, Brucker AJ, Bressler NM, Qin H, Aiello LP, Antoszyk A, Beck RW, Bressler SB, Ferris FL III, Glassman AR, Marcus D, &, Stockdale CR, (2011): Randomized trial evaluating short-term effects of intravitreal ranibizumab or triamcinolone acetonide on macular edema after focal/grid laser for diabetic macular edema in eyes also receiving panretinal photocoagulation. Retina 31: 1009-1027.
24. Gustavsson C, Agardh E, Bengtsson B, &, Agardh CD, (2008): TNF-alpha is an independent serum marker for proliferative retinopathy in type 1 diabetic patients. J Diabetes Complications 22: 309-316.
25. Hartge MM, Unger T, &, Kintscher U, (2007): The endothelium and vascular inflammation in diabetes. Diab Vasc Dis Res 4: 84-88.
26. Jones SA, (2005): Directing transition from innate to acquired immunity: defining a role for IL-6. J Immunol 175: 3463-3468.
27. Kern TS, (2007): Contributions of inflammatory processes to the development of the early stages of diabetic retinopathy. Exp Diabetes Res 2007: 95103.
28. Kim JH, Bachmann RA, &, Chen J, (2009): Interleukin-6 and insulin resistance. Vitam Horm 80: 613-633.
29. Kimura A, &, Kishimoto T, (2010): IL-6: regulator of Treg/Th17 balance. Eur J Immunol 40: 1830-1835.
30. Massin P, Bandello F, Garweg JG, et al., (2010): Safety and efficacy of ranibizumab in diabetic macular edema (RESOLVE Study): a 12-month, randomized, controlled, double-masked, multicenter phase II study. Diabetes Care 33: 2399-2405.
31. Mitchell P, Bandello F, Schmidt-Erfurth U, et al., (2011): The restore study: ranibizumab monotherapy or combined with laser versus laser monotherapy for diabetic macular edema. Ophthalmology 118: 615-625.
32. Mocan MC, Kadayifcilar S, &, Eldem B, (2006): Elevated intravitreal interleukin-6 levels in patients with proliferative diabetic retinopathy. Can J Ophthalmol 41: 747-752.
33. Murugeswari P, Shukla D, Rajendran A, Kim R, Namperumalsamy P, &, Muthukkaruppan V, (2008): Proinflammatory cytokines and angiogenic and anti-angiogenic factors in vitreous of patients with proliferative diabetic retinopathy and eales' disease. Retina 28: 817-824.
34. Nakamura N, Hasegawa G, Obayashi H, et al., (2003): Increased concentration of pentosidine, an advanced glycation end product, and interleukin-6 in the vitreous of patients with proliferative diabetic retinopathy. Diabetes Res Clin Pract 61: 93-101.
35. Sfikakis PP, Grigoropoulos V, Emfietzoglou I, et al., (2010): Infliximab for diabetic macular edema refractory to laser photocoagulation: a randomized, double-blind, placebo-controlled, crossover, 32-week study. Diabetes Care 33: 1523-1528.
36. Sharma RK, Rogojina AT, &, Chalam KV, (2009): Multiplex immunoassay analysis of biomarkers in clinically accessible quantities of human aqueous humor. Mol Vis 15: 60-69.
37. Shinoda K, Ishida S, Kawashima S, et al., (2000): Clinical factors related to the aqueous levels of vascular endothelial growth factor and hepatocyte growth factor in proliferative diabetic retinopathy. Curr Eye Res 21: 655-661.
38. Suzuki Y, Nakazawa M, Suzuki K, Yamazaki H, &, Miyagawa Y, (2011): Expression profiles of cytokines and chemokines in vitreous fluid in diabetic retinopathy and central retinal vein occlusion. Jpn J Ophthalmol 55: 256-263.
39. Tang J, &, Kern TS, (2011): Inflammation in diabetic retinopathy. Prog Retin Eye Res 30: 343-358.
40. World Health Organisation (2006): Global update of available data on visual impairment Book Global update of available data on visual impairment. City: World Health Organisation. Available at: http://www.who.int/blindness. Accessed March 15, 2012.
41. World Medical Association (2008): Declaration of Helsinki-Current (2008) version Book Declaration of Helsinki-Current (2008) version. City: World Medical Association. Available at: http://www.wma.net/en/30publications/10policies/b3/ Index.html. Accessed March 23, 2012.
42. Yoshimura T, Sonoda KH, Sugahara M, et al., (2009): Comprehensive analysis of inflammatory immune mediators in vitreoretinal diseases. PLoS One 4: e8158.
43. Yuuki T, Kanda T, Kimura Y, Kotajima N, Tamura J, Kobayashi I, &, Kishi S, (2001): Inflammatory cytokines in vitreous fluid and serum of patients with diabetic vitreoretinopathy. J Diabetes Complications 15: 257-259.
44. Zhang H, Park Y, Wu J, Chen X, Lee S, Yang J, Dellsperger KC, &, Zhang C, (2009): Role of TNF-alpha in vascular dysfunction. Clin Sci (Lond) 116: 219-230.